Table 2.
PrEP familiarity | Willingness to take PrEP | |||||
---|---|---|---|---|---|---|
B | AOR | 95% CI | B | AOR | 95% CI | |
Between-participant factors (level 2) | ||||||
Age | 0.03 | 1.03 | 0.99, 1.06 | −0.01 | 0.99 | 0.97, 1.02 |
White race (ref = non-White) | −0.41 | 0.66 | 0.31, 1.44 | −0.06 | 0.94 | 0.50, 1.76 |
Gay (ref = bisexual) | 0.82 | 2.28 | 0.80, 6.45 | 0.93 | 2.53* | 1.11, 5.74 |
College degree (ref = no) | −0.26 | 0.77 | 0.34, 1.75 | −0.92 | 0.40** | 0.21, 0.77 |
Month of enrollmenta | 0.10 | 1.10** | 1.02, 1.19 | 0.04 | 1.04 | 0.98, 1.10 |
Within-participant factors (level 1) | ||||||
Partnered (ref = single) | −0.36 | 0.70 | 0.30, 1.64 | −0.55 | 0.58 | 0.29, 1.17 |
Club drug use (ref = no) | 0.89 | 2.44* | 1.12, 5.30 | 0.11 | 1.12 | 0.59, 2.12 |
SC symptomology (ref = no) | −0.40 | 0.67 | 0.33, 1.37 | 0.62 | 1.86* | 1.04, 3.32 |
FDA-approved PrEP (ref = no) | 0.32 | 1.37 | 0.47, 3.98 | −0.52 | 0.59 | 0.25, 1.42 |
Any CAS reported (ref = no) | 0.27 | 1.31 | 0.66, 2.61 | 0.79 | 2.21** | 1.25, 3.91 |
12-month assessment (ref = baseline)b | 0.48 | 1.61 | 0.78, 3.35 | 0.35 | 1.42 | 0.73, 2.77 |
Likelihood of CAS on PrEP | Temptation for CAS on PrEP | |||||
---|---|---|---|---|---|---|
B | AOR | 95% CI | B | AOR | 95% CI | |
Between-participant factors (level 2) | ||||||
Age | −0.02 | 0.98 | 0.95, 1.01 | −0.03 | 0.97 | 0.95, 1.00 |
Gay (ref = bisexual) | 0.39 | 1.47 | 0.57, 3.84 | 0.39 | 1.47 | 0.59, 3.64 |
White race (ref = non-White) | 1.04 | 2.82** | 1.33, 5.98 | 0.42 | 1.53 | 0.75, 3.09 |
College degree (ref = no) | 0.21 | 1.23 | 0.57, 2.69 | 0.73 | 2.08 | 0.99, 4.38 |
Month of enrollmenta | 0.03 | 1.03 | 0.96, 1.10 | 0.03 | 1.03 | 0.97, 1.10 |
Within-participant factors (level 1) | ||||||
Partnered (ref = single) | −0.16 | 0.85 | 0.39, 1.83 | 0.43 | 1.54 | 0.71, 3.32 |
Club drug use (ref = no) | 0.10 | 1.11 | 0.54, 2.29 | 0.04 | 1.04 | 0.50, 2.14 |
SC symptomology (ref = no) | 0.30 | 1.35 | 0.69, 2.63 | 0.84 | 2.32** | 1.21, 4.44 |
FDA-approved PrEP (ref = no) | −0.49 | 0.61 | 0.22, 1.69 | 0.82 | 2.28 | 0.87, 5.95 |
Any CAS reported (ref = no) | 1.71 | 5.51*** | 2.65, 11.46 | 1.27 | 3.57*** | 1.91, 6.66 |
12-month assessment (ref = baseline)b | 0.65 | 1.91 | 0.87, 4.18 | −0.66 | 0.52 | 0.25, 1.07 |
Between-person time was coded as the month of the participant's enrollment (0 through 27), which was mean centered and time invariant (i.e., constant for the same participant over time).
Within-participant time was dichotomously coded as the month of the assessment (BL = 0, 12M = 1) and was time-varying (i.e., differed for the same participant over time). Age and month of enrollment were both mean centered.
P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
FDA, Food and Drug Administration; SC, sexual compulsivity.